Showing 1 posts of 1 posts found.
Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …
Scots neonatal innovations target hearing loss and earlier care
FDA grants De Novo authorisation to light-filtering device for migraine
Southgate opens Innovation Lab for logistics and fulfilment development
Bioptimus partners with Cancer Research Horizons to expand AI cancer data set
Agentis Health Group acquires Clinical Pharmacist Solutions